CNTB
Closed
Connect Biopharma Holdings Ltd
1.06
+0.08 (+8.16%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.98
Day's Range: 1.0251 - 1.07
Send
sign up or login to leave a comment!
When Written:
0.9999
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company headquartered in China. The company is focused on developing and commercializing novel immune modulators for the treatment of autoimmune and inflammatory diseases. Connect Biopharma's lead product candidate, CBP-307, is a small molecule inhibitor of IL-4 and IL-13 signaling pathways, which are implicated in the pathogenesis of multiple autoimmune and inflammatory diseases. The company also has a pipeline of other product candidates targeting various immune pathways. Connect Biopharma has partnerships with several global pharmaceutical companies, including Boehringer Ingelheim and Eli Lilly and Company, for the development and commercialization of its products. The company was founded in 2013 and went public on the NASDAQ in 2021.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








